Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a 2023 Clinical Outlook for clinical stage biotechnology company Tiziana Life Sciences Ltd (NASDAQ:TLSA). He gives his take on what the market can expect from the business this year, saying that it is now "moving forward quite nicely."
Contact Details
Proactive UK Ltd
Proactive UK Ltd
+44 20 7989 0813
